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A B S T R A C T
Background
Diabetes mellitus (DM) confers an increased risk of mortality in young and middle-aged
individuals and in women. It is uncertain, however, whether excess DM mortality continues
beyond age 75 years, is related to type of hypoglycemic therapy, and whether women continue
to be disproportionately affected by DM into older age.
Methods and Findings
From the Cardiovascular Health Study, a prospective study of 5,888 adults, we examined
5,372 participants aged 65 y or above without DM (91.2%), 322 with DM treated with oral
hypoglycemic agents (OHGAs) (5.5%), and 194 with DM treated with insulin (3.3%). Participants
were followed (1989–2001) for total, cardiovascular disease (CVD), coronary heart disease
(CHD), and non-CVD/noncancer mortality. Compared with non-DM participants, those treated
with OHGAs or insulin had adjusted hazard ratios (HRs) for total mortality of 1.33 (95%
confidence interval [CI], 1.10 to 1.62) and 2.04 (95% CI, 1.62 to 2.57); CVD mortality, 1.99 (95%
CI, 1.54 to 2.57) and 2.16 (95% CI, 1.54 to 3.03); CHD mortality, 2.47 (95% CI, 1.89 to 3.24) and
2.75 (95% CI, 1.95 to 3.87); and infectious and renal mortality, 1.35 (95% CI, 0.70 to 2.59) and
6.55 (95% CI, 4.18 to 10.26), respectively. The interaction of age (65–74 y versus 75 y) with DM
was not significant. Women treated with OHGAs had a similar HR for total mortality to men, but
a higher HR when treated with insulin.
Conclusions
DM mortality risk remains high among older adults in the current era of medical care.
Mortality risk and type of mortality differ between OHGA and insulin treatment. Women treated
with insulin therapy have an especially high mortality risk. Given the high absolute CVD
mortality in older people, those with DM warrant aggressive CVD risk factor reduction.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org October 2006 | Volume 3 | Issue 10 | e4001883
PLoSMEDICINE
Introduction
Over the past several decades cardiovascular disease (CVD)
mortality has decreased in the United States [1], while the
prevalence of diabetes mellitus (DM) and its burden of CVD
and coronary heart disease (CHD) have increased [2].
Whether people with DM have had a similar reduction in
CVD mortality compared with individuals without diabetes is
uncertain. A report from the Framingham Heart Study shows
that absolute CVD mortality has decreased in people with
DM, but that the mortality risk relative to individuals without
DM remains unchanged (;2-fold), compared with the 1950s
[3]. A report from New York City likewise shows that CHD
mortality associated with DM has decreased in a similar
measure to that of CHD without DM [4]. On the other hand,
data from two other population studies suggest that CVD and
CHD mortality in people with DM has actually increased,
especially for women [5,6]. These four studies were done in
predominantly middle-aged populations. The situation in
older adults, in whom the incidence and prevalence of DM
and CVD are highest [7], has been studied less fully. It is
possible that the impact of DM is attenuated owing to the
ubiquity of CVD and CHD in older age.
Population-based diabetes mortality studies have adjusted
total and CVD mortality risk using traditional risk factors
such as hypertension, age, sex, and smoking status (reviewed
in [8]). Other factors associated with DM can influence
mortality and serve as confounders. These include low levels
of attained education [9,10], high rates of disability [11],
depression [12,13], and frailty [14,15]. To date, no population-
based study of DM mortality has adjusted estimates for these
factors. CVD mortality is also influenced by several CVD risk
factors that have been recognized and evaluated only in the
last two decades. These include subclinical CVD [16] and
elevated levels of inflammatory factors [17]. Few DM studies
have adjusted mortality risk for these potential factors, and
none simultaneously.
The Cardiovascular Health Study (CHS) is a longitudinal,
observational study of adults aged 65 years or older. It has
accrued more than 11 years of follow-up information in the
current era of medical care with a high degree of detail. In the
present study we describe mortality in older people with DM
treated with oral hypoglycemic agents (OHGAs) and insulin.
We adjust for traditional and nontraditional covariates to
ensure that the severity of DM is not the explanation for
differences that are found.
Methods
Recruitment methods for CHS have been published [18]. In
brief, a random sample of individuals, 65 y of age or above,
derived from Medicare eligibility lists, and other household
members 65 y or above, were invited to participate in the
study. Potential participants were excluded if they were
institutionalized, were unable to attend clinic visits, or had
illnesses that were expected to lead to early death. Of those
who were contacted, 9.6% were ineligible and 34.9% refused
participation [18]. In total 5,201 participants were recruited
in 1989–1990 and 687 in 1992–1993 to provide additional
representation of African Americans. All participants signed
informed consent forms upon entry into the study. Data for
these analyses were from 1989 through 2001.
Upon entry into the study, participants were invited for a
baseline interview. Information on prescription medications
used in the preceding two weeks (including insulin and
OHGAs) and psychosocial function were collected [19]. During
a subsequent clinic visit, venipuncture was performed after an
overnight fast. Plasma and serum were frozen at 70 8C, and
shipped to the CHS Central Laboratory [20].
Followingblooddrawing, participants underwent the follow-
ing cardiovascular tests: (1) resting ECG, (2) ankle and arm
blood pressures, and (3) carotid artery ultrasounds [18]. Details
of past medical history were obtained during the clinic visit.
Definition of DM and Non-DM
For these analyses, DM is defined as pharmacologically
treated disease (OHGAs and/or insulin) at baseline. Partic-
ipants with fasting glucose (FG) over 125 mg/dl without a
history of DM and not on hypoglycemic medications were not
considered to have DM. There were 441 participants with no
history of DM with baseline FG . 125 mg/dl. Of these
participants, 155 (35.1%) received pharmacologic therapy
during follow up. Preliminary analyses showed that the
mortality of these participants differs from that of pharma-
cologically treated participants with DM at baseline and is the
subject of another manuscript. In this paper these 441
participants were included in the ‘‘nondiabetic’’ group.
Definition of Baseline CVD
Baseline clinical CHD was defined as a history of
myocardial infarction, angina pectoris, or a revascularization
procedure (coronary artery bypass grafting or percutaneous
transluminal coronary angioplasty). CVD at baseline includes
CHD and a history of stroke or transient ischemic attacks.
Isolated subclinical CVD was defined as the presence of any
of the following in the absence of any clinical CVD: ankle/arm
index below 0.9 in the absence of claudication or peripheral
arterial disease surgery; major ECG changes in the absence of
prevalent CHD; and common and internal carotid artery
intima-media thickness in the upper 20% of the distribution
or common carotid stenosis over 25%. These criteria have
been used in prior CHS studies [16].
Baseline Functional and Psychosocial Factors
Participants answered several standard interviewer-admin-
istered questionnaires on physical and cognitive function and
psychosocial factors. Physical functioning was ascertained
using a modified version of the Health Interview Supplement
on Aging questionnaire [21], from which difficulties with
activities of daily living (ADLs) and instrumental ADLs
(IADLs) were derived. In addition, two questions regarding
self-assessed quality of life were asked.
Depression was measured using the Center for Epidemio-
logic Studies Depression Scale [21]. A total of ten questions
were asked about how the participant had felt in the preceding
week. They were scored on a scale of 0 to 3. The higher the
score, the more depressed was the person (range 0 to 30).
Cognitive function was measured by the Mini-Mental State
examination [22] and the Digit-Symbol Substitution test [23].
Baseline Frailty
Baseline frailty was defined using a clinical phenotype that
has been validated in the CHS [24]. This phenotype is met by
having three or more of the following five measured criteria:
(1) unintentional weight loss of more than 4.54 kg (10 lb) in
PLoS Medicine | www.plosmedicine.org October 2006 | Volume 3 | Issue 10 | e4001884
Mortality in Older Diabetic Adults
the preceding year; (2) weakness defined as grip strength in
the lowest 20% by gender and body mass index; (3)
exhaustion by self-report of being tired most of the time or
always with any effort, or stating ‘‘I cannot get going’’; (4)
slowness defined as the lowest 20% by gender and height for
time to walk 4.6 m (15 ft); (5) low exercise tolerance as defined
by the lowest 20% for males (,383 Kcal/wk) and females
(,270 Kcal/wk), based on the short version of the Minnesota
Leisure Time Activity Questionnaire [25]. Those with one or
two criteria were considered ‘‘pre-frail,’’ an intermediate
syndrome with increased risk for the development of frailty.
Follow-Up and Ascertainment and Verification of Mortality
Participants were contacted every six months. Contacts
alternated between a telephone interview and a clinic
examination. At each contact, participants were asked about
cardiovascular events and hospitalizations. Discharge sum-
maries and diagnoses were obtained for all hospitalizations,
including fatal events. Those who had died were often
identified by family members or friends and reviews of
obituaries. For potential incident cardiovascular events and
death, additional information was collected, including car-
diac enzymes, serial ECGs, death certificates, autopsy reports,
interviews of next of kin, and physician questionnaires. All
deaths were reviewed by the CHS Events Committee and
classified into one of five major groups: (1) atherosclerotic
CHD; (2) cerebrovascular disease; (3) atherosclerotic disease
other than CHD (other ASCVD, such as abdominal aortic
aneurysm or ischemic bowel); (4) other cardiovascular
diseases (such as valvular heart disease or pulmonary
embolism); and (5) all other deaths (with causes specified in
text fields). The term ‘‘combined CVD mortality’’ is used to
denote death from causes 1–4.
Statistical Analysis
Kaplan-Meier curves were computed to estimate the
survival curves for the various causes of death. Cox propor-
tional hazards regression was used to estimate the hazard
ratios (HRs) for diabetes status with and without adjustment
for significant predictors of mortality determined by back-
ward elimination from among the variables listed in Table 1.
The log rank test was used to test the statistical significance of
differences in survival as a function of diabetes status. Time-
dependent interactions were included in the initial models to
determine if the proportional hazards assumption of the Cox
model were violated. In all instances, the resulting test of the
interactions was nonsignificant, and the interaction terms
were not included in the final models.
All analyses used Stata 8.0 (Stata, College Station, Texas,
United States).
Results
There were 5,372 participants without DM (91.2% of the
cohort), 322 with DM treated with OHGAs (5.5%), and 194
with DM treated with insulin, with or without OHGAs (3.3%)
(11 participants were on both insulin and OHGAs). Baseline
characteristics are shown in Table 1. As compared with those
with DM treated with either OHGAs or insulin, those without
DM were more likely to be female; to be less centrally obese;
to have less history of prior CHD, stroke, or CHF; and to have
lower blood pressure and slower heart rate. They also had
lower markers of inflammation, fewer difficulties with ADLs
and IADLs, and were more likely to report good health. As
compared with participants treated with OHGAs, those
treated with insulin with or without OHGAs were more likely
to smoke and to have a history of CVD and prevalent CVD.
During a median follow-up of 11.1 y (maximum 12.1 y)
2,391 (40.7%) of the 5,888 participants died. Causes of death
are listed in Table 2. CHD mortality was higher among
participants with DM. There were no large differences with
regard to stroke death. Noncardiovascular causes of death,
especially cancer, were more common among non-DM
participants. Among OHGA-treated participants, deaths
due to dementia and renal disease were common (;22%
and ;8%, respectively), whereas among those treated with
insulin therapy, infectious causes and renal disease were more
common (;29% and ;13%, respectively).
Cumulative mortality plots for total, combined CVD, and
non-CVD endpoints are shown in Figure 1A. Median survival
for those without DM was over 12 y. For those with DM
treated with OHGA, median survival was slightly less than 10
y. For those treated with insulin, median survival was ;7.5 y,
with 75% dead by 12 y follow-up. While most of the difference
in mortality between those with and without DM was related
to combined CVD (Figure 1B), especially CHD (Figure 1C),
overall the non-CVD causes (Figure 1D)—especially infection,
renal disease, and metabolic disease (Figure 1E)—accounted
for a large percentage of the difference in survival.
Within the diabetes cohort, insulin-treated participants
had higher total mortality than those treated with OHGAs.
This difference was mostly accounted for by increased non-
CVD mortality (especially renal, infectious, and metabolic
causes; see Figures 1E and S1). There was little difference in
combined CVD or CHD mortality in those treated with
OHGAs or insulin. A test for nonproportional hazards (i.e.,
nonconstant HRs across time) was nonsignificant for the
diabetes variable, suggesting that the apparent widening of
the gap between the curves in Figure 1 may be due to chance.
Incidence rates for mortality endpoints, with unadjusted
and adjusted HRs, are shown in Table 3 (a list of factors
significantly associated with each endpoint can be found in
Protocol S1). For most endpoints, incidence and relative risk
increased stepwise between participants without DM and
participants with DM treated with OHGAs and those treated
with insulin. There were no differences for cancer. Unad-
justed and age- and gender-adjusted relative risk estimates
showed similar findings. Fully adjusted analyses, however,
diminished the relative risk of death from stroke. Full
adjustment attenuated the relative risk associated with
diabetes category for total, combined CVD, and CHD
mortality, and made the relative risk for non-CVD death
significant only in DM participants treated with insulin.
Age and Gender Analyses
When a dichotomous variable for age (65–74 y versus.74 y)
was entered into our models its interaction with diabetes
status was not significant. There was, however, a highly
significant interaction of gender with diabetes status (p ,
0.001) (Table 4). Women with DM had a somewhat higher
relative total mortality risk than women without DM (HR 2.28
[95% confidence interval (CI), 1.90 to 2.72]), as compared with
the relative mortality risk of men with DM versus men without
DM (HR 1.80 [95% CI, 1.63 to 2.11]). When analyses were
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limited to participants treated with OHGAs, HRs were almost
identical (women, HR 1.62 [95% CI, 1.26 to 2.09]); men, HR
1.63 [95% CI, 1.33 to 2.00]). On the other hand, the relative
mortality risk associated with insulin therapy was higher in
women than in men. Women on insulin had the same
mortality as men on insulin therapy (Figure S2).
Table 1. Baseline Factors of 5,888 Cardiovascular Health Study Participants Followed from 1989 to 2001 Categorized by Glycemic
Status and Type of Antihyperglycemic Treatment
Category Factor Individual
Characteristic
Diabetes Medications
None
(n ¼ 5,372)
OHGA Alone
(n ¼ 322)
Insulin with or without OHGA
(n ¼ 194)
Demographic factors Age Mean, y 72.9 72.7 72.4
65–74, % 66.0 66.5 68.6
74–79, % 20.1 23.3 21.7
.80, % 13.9 10.2 9.8
Gender Male, % 41.7 50.9 47.9
Race White, % 85.1 68.6 69.6
Smoking status Never smoked 46.7 48.4 39.7
Former smoker 41.3 43.5 46.4
Current smoker 12.1 8.1 13.9
Total alcohol per wk, oz 2.58 0.96 1.27
Weight factors Weight, lb 159.0 174.4 173.2
Body mass index, kg/m2 26.5 28.56 28.3
Waist circumference, cm 94.0 101.2 100.3
Hip circumference, cm 101.7 105.0 104.5
Baseline CVD History of CHD, % 18.3 32.0 36.1
History of stroke, % 4.0 6.5 8.3
History of CHF, % 4.0 7.8 16.0
Clinical CVD, % 29.2 46.9 53.1
Isolated subclinical CVD, % 59.2 78.9 75.8
Ankle/arm index 1.07 1.02 0.97
Systolic blood pressure, mm Hg 136.1 141.6 142.1
Diastolic blood pressure, mm Hg 70.8 70.5 70.1
Heart rate, per 30 s 33.8 35.1 36.1
Baseline laboratory Cholesterol, mg/dl 212.1 202.0 201.5
LDL, mg/dl 130.5 123.0 121.7
HDL, mg/dl 54.9 47.3 47.1
Triglyceride, mg/dl 136.7 162.7 183.2
Fibrinogen, mg/dl 322.0 336.4 354.8
C-reactive protein, mg/l 3.5 5.8 5.2
Creatinine, mg/dl 1.06 1.02 1.17
White blood cell count 6.3 6.8 7.2
Fasting insulin, lIU/ml 14.6 19.8 84.4
Fasting glucose, mg/dl 104.6 178.9 183.3
Baseline carotid artery
and ECG studies
Maximum common carotid IMT, mm 1.06 1.14 1.18
Maximum internal carotid IMT, mm 1.43 1.55 1.61
ECG left ventricular mass, g 153.0 170.1 166.2
ECG left ventricular hypertrophy, % 4.9 5.8 5.9
ECG major or minor abnormality, % 29.2 44.2 41.2
Atrial fibrillation, % 2.6 3.7 3.6
Psychosocial factors ADLs.1, % 3.0 6.9 3.6
IADLs.0, % 25.1 30.2 37.3
Depression scale, total 4.6 5.5 5.9
Education High school or less, % 44.3 37.0 33.7
Exercise No exercise, % 8.6 13.0 11.9
Low intensity, % 47.4 47.2 53.6
Moderate Intensity, % 34.5 34.2 29.9
High intensity, % 9.5 5.6 4.6
Total physical activity, Kcal 1,739 1,378 1,406
15-Foot timed walk, s 5.76 6.37 6.66
Self-perceived health (excellent/very good), % 39.5 18.1 16.0
Digit symbol score 36.9 31.6 30.5
Mini-Mental score (30-point scale) 27.6 26.7 27.0
Frailty Not frail, % 47.6 35.1 31.5
Intermediate, % 46.0 53.4 54.3
Frail, % 6.4 11.5 14.2
IMT, intima-media thickness.
DOI: 10.1371/journal.pmed.0030400.t001
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Discussion
In this observational study from the era of current medical
care we found that DM continues to be associated with a
deleterious effect on mortality in older adults. The relative
risk of total mortality for participants treated with OHGA
and insulin relative to those without DM was 1.7 and 2.8,
respectively. Adjustment for traditional CVD risk factors—
age, gender, smoking, psychosocial factors (depression, frailty,
and diminished cognitive function)—and newly recognized
CVD risk factors (inflammation factors and isolated sub-
clinical CVD)—decreased the relative risk to ;1.3 and 2.0,
respectively. The total mortality risk estimate for OHGA
users is lower than that of prior studies, while the estimate for
insulin users is in line with prior studies [8]. These results
emphasize the importance of assessing treatment type.
For combined CVD and CHD mortality, adjusted mortality
risk was ;2 and 2.5 times higher (respectively) than in
participants without DM. These estimates are similar to those
from studies of older individuals with diabetes from prior
decades, which adjusted for traditional CVD risk factors such
as age, gender, smoking, and hypertension [8,26,27]. From our
results two conclusions may be derived. First, given the
decreasing rate of CVD and CHD mortality in the general
population, but the unvarying relative risk of mortality
associated with DM, it follows that older adults with DM are
experiencing the same rate of decline in CVD and CHD
mortality as people without DM. Second, the adjusted relative
risks of CVD and CHD mortality that were similar to prior
studies suggest that additional adjustment for subclinical
CVD and inflammation as well as for psychosocial factors do
not help explain the excess CVD and CHD mortality
associated with DM. Only for stroke mortality, among
measured CVD outcomes, was adjusted relative risk not
significantly increased compared with people without DM
and lower in incidence rate than that reported in prior
decades. This result can be interpreted in several ways. It may
signify that the many factors that we adjusted for accounted
for differences in stroke risk. Alternatively, some of these
factors are plausibly consequences of DM, and thus the
decrease in risk associated with DM is a consequence of
‘‘overadjustment’’ for factors in the causal pathways leading
to death. Also, our strict definition of DM (pharmacologically
treated) most probably excluded people considered to have
Table 2. Causes of Death in CHS Participants Followed from 1989 to 2001 Categorized by Baseline Glycemic Status and Type of
Antihyperglycemic Treatment
Mortality Mortality Subtype Totals % Diabetes Medications
None OHGA Insulin
(with or without OHGA)
Count Percent of
Mortality
Count Percent of
Mortality
Count Percent of
Mortality
Cause of deatha Atherosclerotic CHD 635 26.6 509 24.4 76 45.2 50 35.7
Cerebrovascular disease 225 9.4 200 9.6 16 9.5 9 6.4
Other artherosclerotic disease 55 2.3 40 1.9 6 3.6 9 6.4
Other cardiovascular 65 2.7 59 2.8 4 2.4 2 1.4
Noncardiovascular
(all other causes of death)
1,387 58.0 1,253 60.2 64 38.1 70 50.0
Unknown 24 1.0 22 1.1 2 1.2 0 0.0
Total 2,391 2,083 168 140
Causes of
noncardiovascular deathb
Trauma 52 3.7 49 3.9 1 1.6 2 2.9
Dementia 205 14.7 183 14.6 14 21.9 8 11.4
Amyotrophic lateral sclerosis 6 0.4 6 0.5 0 0.0 0 0.0
Parkinson disease 30 2.2 28 2.2 0 0.0 2 2.9
Epilepsy 3 0.2 3 0.2 0 0.0 0 0.0
Pulmonary embolism 1 0.1 1 0.1 0 0.0 0 0.0
Respiratory causes 127 9.1 119 9.5 4 6.3 4 5.7
Pneumonia 113 8.1 97 7.7 5 7.8 11 15.7
Infection 12 0.9 10 0.8 1 1.6 1 1.4
Sepsis 43 3.1 33 2.6 2 3.1 8 11.4
Liver disease 12 0.9 10 0.8 2 3.1 0 0.0
Gastrointestinal disease 56 4.0 52 4.2 3 4.7 1 1.4
Renal failure 42 3.0 28 2.2 5 7.8 9 12.9
Metabolic conditions 7 0.5 3 0.2 2 3.1 2 2.9
Amyloid 4 0.3 4 0.3 0 0.0 0 0.0
Fractures 40 2.9 37 3.0 2 3.1 1 1.4
Failure to thrive 16 1.2 16 1.3 0 0.0 0 0.0
Myelodysplastic syndrome 10 0.7 10 0.8 0 0.0 0 0.0
Other musculoskeletal diseases 5 0.4 4 0.3 1 1.6 0 0.0
Cancer 603 43.4 560 44.7 22 34.4 21 30.0
aPercents are based on the totals of all deaths.
bPercents are of those dying of noncardiovascular causes.
DOI: 10.1371/journal.pmed.0030400.t002
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Figure 1. Mortality in Cardiovascular Health Study Participants According to Glycemic Status and the Type of Antihyperglycemic Treatment
The cohort consisted of 5,372 participants without DM, 322 with DM treated with OHGAs, and 194 with DM treated with insulin with or without OHGAs
followed from 1989 to 2001.
(A) Total mortality of the cohort is plotted with regard to diabetes status.
(B) Mortality due to CVD.
(C) Mortality due to CHD.
(D) Mortality due to noncardiovascular causes.
(E) Mortality due to sepsis, metabolic derangement, and renal disease.
DOI: 10.1371/journal.pmed.0030400.g001
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DM in prior studies. For example, only 6%–9% of the total
diabetes mortality in this study was due to stroke, lower than
the mortality attributed to stroke in prior studies [28,29].
Last, our stroke findings could be the result of type 2 error
owing to the small number of stroke deaths.
With regard to age, participants with DM aged 75 years or
older had similar relative mortality rates as those below 75
years of age, consistent with a study based on 1990s Medicare
claims data, which demonstrated excess mortality risk from
DM in every age group [30]. Given the high absolute CVD
mortality in people over the age of 70 years, the relative risk
of ;2–2.5 reported herein is far more noteworthy and of
greater public health impact than a similar relative risk in a
middle-aged population. Elderly people often receive less
intensive management of CVD risk factors than younger
individuals [31]. Our findings strengthen the rationale for the
opposite approach.
As to gender, women with versus women without DM had a
greater relative total mortality risk compared to men with
versus men without DM (HR 2.28 [95% CI, 1.90 to 2.72] versus
1.80 [95% CI, 1.53 to 2.11]). When this risk was categorized by
treatment type it was found that women treated with OHGAs
Table 3. Incidence Rates and HRs for Total, CVD, and Non-CVD Endpoints in CHS Participants Categorized by Baseline Glycemia Status
and Type of Antihyperglycemic Treatment
Cause of Death Group Deaths, n Incidence Rate
Per 100 Person-Years
Unadjusted HR
(95% CI)
Model 1 HR
(95% CI)
Model 2 HR
(95% CI)
Total Non-DM 2,081 4.1 1.00 1.00 1.00
DM OHGA 168 6.6 1.70 (1.46 to 1.99) 1.74 (1.49 to 2.04) 1.33 (1.10 to 1.62)
DM insulin 142 10.3 2.81 (2.37 to 3.34) 2.82 (2.37 to 3.34) 2.04 (1.62 to 2.57)
Combined CVDa Non-DM 807 1.6 1.00 1.00 1.00
DM OHGA 102 4.0 2.63 (2.14 to 3.23) 2.67 (2.17 to 3.28) 1.99 (1.54 to 2.57)
DM insulin 71 5.1 3.52 (2.76 to 4.50) 3.53 (2.76 to 4.52) 2.16 (1.54 to 3.03)
CHD Non-DM 508 1.0 1.00 1.00 1.00
DM OHGA 76 3.0 3.10 (2.43 to 3.94) 3.10 (2.44 to 3.95) 2.47 (1.89 to 3.24)
DM insulin 51 3.7 3.97 (2.97 to 5.32) 3.90 (2.91 to 5.23) 2.75 (1.95 to 3.87)
Stroke Non-DM 200 0.4 1.00 1.00 1.00
DM OHGA 16 0.6 1.68 (1.01 to 2.80) 1.77 (1.06 to 2.95) 1.36 (0.75 to 2.46)
DM insulin 9 0.7 1.86 (0.95 to 3.64) 1.96 (1.00 to 3.83) 1.40 (0.68 to 2.91)
Non-CVDb Non-DM 1,274 1.4 1.00 1.00 1.00
DM OHGA 66 1.7 1.35 (0.99 to 1.83) 1.45 (1.07 to 1.97) 1.25 (0.87 to 1.80)
DM insulin 71 3.6 3.09 (2.31 to 4.13) 3.20 (2.39 to 4.28) 3.12 (2.21 to 4.41)
Cancer Non-DM 559 1.1 1.00 1.00 1.00
DM OHGA 22 0.9 0.81 (0.53 to 1.24) 0.79 (0.51 to 1.21) 0.69 (0.44 to 1.07)
DM insulin 22 1.5 1.49 (0.97 to 2.31) 1.44 (0.93 to 2.22) 1.26 (0.81 to 1.96)
Sepsis, metabolic, renal,
or pneumonia
Non-DM 161 0.3 1.00 1.00 1.00
DM OHGA 14 0.5 1.84 (1.07 to 3.18) 2.00 (1.16 to 3.45) 1.35 (0.70 to 2.59)
DM insulin 30 2.2 7.88 (5.32 to 11.66) 8.50 (5.73 to 12.61) 6.55 (4.18 to 10.26)
Model 1 is adjusted for age andgender;model 2 is adjusted for age, gender, and factors that predictmortality for eachendpoint. SeeProtocol S1 for covariates thatwere adjusted for inmodel 2.
aCombined CVD includes atherosclerotic CHD, cerebrovascular disease, other ASHD, and other cardiovascular.
bIncludes 24 with unknown cause of death.
DOI: 10.1371/journal.pmed.0030400.t003
Table 4. Incidence Rates and HRs for Total Mortality in Men and Women with Diabetes as Compared to Those without Diabetes from
the Cardiovascular Health Study Followed 1989–2001
Group Gender Diabetes No Diabetes HR (95% CI)a p-Value
Deaths, n Incidence Rate
Per 100 Person-Years
Deaths, n Incidence Rate
Per 100 Person-Years
All participants with DM
versus those without DM
Women 137 6.7 1,006 3.3 2.28 (1.90 to 2.72) ,0.001
Men 173 9.2 1,075 5.4 1.80 (1.53 to 2.11) ,0.001
Participants with DM on OHGA therapy
versus participants without DM
Women 66 5.0 1,006 3.3 1.64 (1.28 to 2.10) ,0.001
Men 102 8.3 1,075 5.4 1.61 (1.31 to 1.97) ,0.001
Participants with DM on insulin therapy
versus participants without DM
Women 71 9.9 1,006 3.3 3.61 (2.83 to 4.60) ,0.001
Men 71 10.7 1,075 5.4 2.15 (1.69 to 2.73) ,0.001
aThe comparison group for each row is the group of the same sex without DM.
DOI: 10.1371/journal.pmed.0030400.t004
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had mortality risk similar to that of men, but a much higher
relative mortality than men when treated with insulin
therapy. Thus the overall increased mortality of women than
men with DM appears to be accounted for by insulin therapy.
This finding has not, to our knowledge, yet been reported.
The increased relative mortality with insulin therapy for
women with DM was due mainly to the lower risk of death in
women without DM [26], since women and men with DM
treated with insulin both had similarly high cumulative
mortality (.75% at 12 y).
Limitations of this study should be noted. First, we may
have overadjusted in our multivariable Cox models, since
many of the factors examined may be in the causal pathway
or strongly associated with causal factors that lead to the
mortality, thus potentially underestimating the effect of
diabetes. Nonetheless, our analyses demonstrate that differ-
ences in mortality exist between those with and without DM
and between those taking and not taking insulin therapy,
even after accounting for the presence or absence of such
potent predictors of mortality as clinical and subclinical
CVD, dementia, and functional status.
Second, our definition of DM required that pharmacolog-
ical therapy be used. Those with FG over 125 mg/dl, but not
on such therapy, were included in the group without diabetes.
The result was to include in the nondiabetes cohort ;3%
who went on to receive antidiabetes pharmacologic therapy
and 8.2% who may have persisted in having elevated FG levels
but were not on pharmacologic therapy. The effect of this
would be to bias our estimates to the null and make them
conservative. Our preliminary analyses indicate that mortal-
ity in these newly diagnosed DM participants is slightly less
than that of participants with established DM. In addition, a
substantial fraction of these patients with ‘‘new-onset’’ DM
may not have had diabetes at all, in that when retested their
glucose levels were within the nondiabetes range.
Third, CHS did not collect data on the duration of DM
prior to enrollment. This is a deficiency, since duration of DM
is an important factor in DM mortality. Participants on
insulin, for example, may have had greater duration of DM.
Nonetheless, factors that would be associated with diabetes
duration—such as the extent of subclinical CVD and the
presence of senescence and mobility disorders, e.g., frailty—
did not explain the differences in mortality between those
with or without DM and those treated and not treated with
insulin. Finally, the entire CHS cohort was limited to people
who were living at home, who were not institutionalized, and
who were healthy enough (initially) to attend clinic visits. As
such, our results are likely conservative estimates since DM
most probably has a greater mortality effect in those with
serious chronic illnesses.
In conclusion, DM continues to exert a strong negative
impact on mortality in older adults in the current era of
medical care. This effect is not explained by traditional and
newer CVD risk factors. The negative effect of DM persists
into advanced older age. Individuals, especially women,
treated with insulin are at a much higher risk of death than
those treated with OHGAs, especially from renal and
infectious causes.
Supporting Information
Figure S1.MortalityCurvesShowing theRelativeProportionsofCauses
ofDeath byGlycemic Status andType ofAntihyperglycemic Treatment
Mortality curves are based on the Cox models. The cohort consisted
of 5,372 participants without DM, 322 with DM treated with OHGAs,
and 194 treated with insulin with or without oral hypoglycemic
agents followed from 1989 to 2001.
Found at DOI: 10.1371/journal.pmed.0030400.sg001 (237 KB DOC).
Figure S2. Cumulative Total Mortality Categorized by Gender,
Diabetes Status, and Type of Antihyperglycemic Treatment
Cohort included 5,372 participants without DM, 322 with DM treated
with OHGAs, and 194 treated with insulin with or without oral
hypoglycemic agents followed from 1989 to 2001.
Found at DOI: 10.1371/journal.pmed.0030400.sg002 (29 KB DOC).
Protocol S1. Statistically Significant Covariates on Cox Proportional
Hazards Modeling for Table 3
Found at DOI: 10.1371/journal.pmed.0030400.sd001 (50 KB DOC).
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Editors’ Summary
Background. Diabetes is a growing global health problem. By 2030, 300
million people worldwide may have this chronic, incurable disorder,
double the current number. People with diabetes have dangerously high
amounts of sugar in their blood. Blood-sugar levels are normally
controlled by insulin, a hormone made by the pancreas that tells cells to
absorb sugar from the blood. This control fails in people with diabetes,
either because they make no insulin (type 1 diabetes) or because their
cells are insensitive to insulin (type 2 diabetes). Type 1 diabetes is
controlled with insulin injections; type 2 diabetes is controlled with diet,
exercise, and pills that reduce blood-sugar levels. Long-term complica-
tions of diabetes include kidney failure, blindness, and nerve damage.
Individuals with diabetes also have an increased risk of developing
cardiovascular disease (CVD)—heart problems, strokes, and poor
circulation—because of damage to their blood vessels.
Why Was This Study Done? Epidemiological studies (investigations of
disease patterns, causes, and control in populations) have indicated that
diabetes increases the risk of death (mortality) from CVD in young and
middle-aged people, but it is not known whether this is also true for old
people. It is also not known what effect long-term treatment for diabetes
has on mortality or whether the risk of death from CVD is decreasing in
diabetic people as it is in the general US population. This information
would help physicians provide health care and lifestyle advice to people
with diabetes. In this study, the researchers have investigated mortality
patterns in elderly diabetic people by looking at data collected between
1989 and 2001 by the US Cardiovascular Health Study, an observational
study of nearly 6,000 people aged over 65 years (in this type of study
participants are observed without imposing any specific changes to their
lifestyle, behavior, medical care, or treatments).
What Did the Researchers Do and Find? Participants were screened at
the start of the Cardiovascular Health Study for CVD and diabetes
(defined as drug-treated disease), for established CVD risk factors such as
high blood pressure and smoking, for recently recognized CVD risk
factors (for example, subclinical CVD), and for psychosocial factors
associated with diabetes that might influence mortality, such as frailty
and depression. At this time, about 5% of the participants were taking
oral hypoglycemic agents for diabetes and about 3% were taking insulin.
During the 11-year study, 40% of the participants died. After adjusting
for CVD risk factors and psychosocial factors, the researchers calculated
that people treated with oral hypoglycemic agents were 1.3 times as
likely to die from all causes and people treated with insulin were twice as
likely to die as people without diabetes. The risk of death from CVD was
about twice as high in both groups of diabetic participants as in non-
diabetic participants; the risk of death from coronary heart disease was
increased about 2.5-fold. These adjusted relative risks are very similar to
those found in previous studies. The researchers also report that
participants treated with insulin were six times more likely to die from
infectious diseases or renal failure than nondiabetic participants, and
women treated with insulin had a particularly high mortality risk.
What Do These Findings Mean? These findings indicate that the
negative impact on mortality of diabetes persists into old age and that
death from CVD is currently declining in both older diabetic people and
nondiabetic people. In addition, they show that diabetic people treated
with insulin are at a greater risk of dying relative to people without
diabetes and those taking oral hypoglycemic agents. This might reflect
the type of diabetes that these people had, but this was not
investigated. How long participants had had diabetes was also not
considered, nor how many people developed diabetes during the study.
These and other limitations might mean that the reported excess
mortality due to diabetes is an underestimate. Nevertheless, the estimate
that elderly people with diabetes are twice as likely to die from CVD as
people without diabetes is important. Many elderly people die anyway
because of CVD, so this increased risk represents many more deaths than
the similar increased risk in younger diabetic populations. Yet, elderly
people often receive less-intensive management of CVD risk factors than
younger people. The results of this study suggest that rectifying this
situation could prolong the lives of many elderly people with diabetes.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030400.
 MedlinePlus encyclopedia has pages on diabetes, heart disease, stroke
and poor circulation
 The US National Institute of Diabetes and Digestive and Kidney
Diseases provides patient information on diabetes
 Information for patients on prevention, diagnosis, and management of
diabetes is available from the America Diabetes Association
 Patient information is available from the American Heart Association
on all aspects of heart disease, including its association with diabetes
 Wikipedia pages on diabetes and cardiovascular disease (note that
Wikipedia is a free online encyclopedia that anyone can edit)
 Further information is available about the Cardiovascular Health Study
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